MA52586A - Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b - Google Patents
Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite bInfo
- Publication number
- MA52586A MA52586A MA052586A MA52586A MA52586A MA 52586 A MA52586 A MA 52586A MA 052586 A MA052586 A MA 052586A MA 52586 A MA52586 A MA 52586A MA 52586 A MA52586 A MA 52586A
- Authority
- MA
- Morocco
- Prior art keywords
- hepatitis
- virus
- treatment
- induced diseases
- dihydropyrimidine derivatives
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title 2
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical class C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18171262 | 2018-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52586A true MA52586A (fr) | 2021-03-17 |
Family
ID=62143008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052586A MA52586A (fr) | 2018-05-08 | 2019-05-07 | Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210220356A1 (fr) |
| EP (1) | EP3790866A4 (fr) |
| JP (1) | JP2021523160A (fr) |
| KR (1) | KR20210006412A (fr) |
| CN (1) | CN112638883A (fr) |
| AU (1) | AU2019266729A1 (fr) |
| CA (1) | CA3097784A1 (fr) |
| MA (1) | MA52586A (fr) |
| WO (1) | WO2019214610A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (fr) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Formulations d'anticorps anti-tnf alpha |
| AU2018291688B2 (en) | 2017-06-27 | 2022-02-03 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| WO2022257942A1 (fr) * | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection au vhb ou de maladies induites par le vhb |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19817264A1 (de) * | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| AU3009801A (en) * | 1999-12-22 | 2001-07-03 | Bayer Aktiengesellschaft | Combinations of medicaments for treating viral diseases |
| DE10013126A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| WO2010069147A1 (fr) * | 2008-12-17 | 2010-06-24 | 张中能 | Derives de la dihydropyrimidine, leurs compositions et leur utilisation |
| EP2800742B1 (fr) * | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 1,4-dihydropyrimidines 4,4-disubstitués et utilisation associée en tant que médicaments pour le traitement de l'hépatite b |
| CN104926808B (zh) * | 2012-08-24 | 2018-09-14 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| AU2018291688B2 (en) * | 2017-06-27 | 2022-02-03 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
-
2019
- 2019-05-07 KR KR1020207034660A patent/KR20210006412A/ko not_active Withdrawn
- 2019-05-07 CN CN201980045816.7A patent/CN112638883A/zh active Pending
- 2019-05-07 MA MA052586A patent/MA52586A/fr unknown
- 2019-05-07 EP EP19800095.2A patent/EP3790866A4/fr not_active Withdrawn
- 2019-05-07 US US17/053,737 patent/US20210220356A1/en not_active Abandoned
- 2019-05-07 AU AU2019266729A patent/AU2019266729A1/en not_active Abandoned
- 2019-05-07 WO PCT/CN2019/085838 patent/WO2019214610A1/fr not_active Ceased
- 2019-05-07 JP JP2020562762A patent/JP2021523160A/ja not_active Withdrawn
- 2019-05-07 CA CA3097784A patent/CA3097784A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210006412A (ko) | 2021-01-18 |
| WO2019214610A1 (fr) | 2019-11-14 |
| AU2019266729A1 (en) | 2021-03-11 |
| US20210220356A1 (en) | 2021-07-22 |
| CN112638883A (zh) | 2021-04-09 |
| EP3790866A1 (fr) | 2021-03-17 |
| JP2021523160A (ja) | 2021-09-02 |
| EP3790866A4 (fr) | 2022-03-02 |
| CA3097784A1 (fr) | 2019-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53023A (fr) | Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b | |
| MA52586A (fr) | Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b | |
| EP4185330A4 (fr) | Complexes de ciblage musculaire et leurs utilisations dans le traitement de dystrophinopathies | |
| MA45550A (fr) | Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b | |
| MA55286A (fr) | Dérivés de pyrimidone à cycles fusionnés destinés à être utilisés dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b | |
| MA55020A (fr) | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b | |
| MA54560A (fr) | Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b | |
| EP4076444A4 (fr) | Dérivés d'indazole et leurs méthodes d'utilisation dans le traitement de l'herpès virus | |
| PH12018550150A1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| MA52661A (fr) | Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b | |
| MA54556A (fr) | Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b | |
| MA53193A (fr) | Vidofludimus à utiliser dans le traitement ou la prévention de maladies virales | |
| EP3416675A4 (fr) | Traitement de l'infection par le virus de l'hépatite delta par interféron lambda | |
| EP3600305A4 (fr) | Formulations d'alcaloïde berbérine dans la prévention et/ou le traitement d'une maladie infectieuse | |
| EP4037706A4 (fr) | Compositions et méthodes de traitement d'une infection par le virus de l'hépatite b | |
| BR112022000971A2 (pt) | Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv | |
| MA55720A (fr) | Polythérapie pour le traitement d'une infection par le virus de l'hépatite b | |
| EP3837277A4 (fr) | Virus de la maladie de newcastle recombinés et leurs utilisations pour la prévention d'une maladie à rsv ou d'une maladie à métapneumovirus humain | |
| PH12021550632A1 (en) | Monomer and multimeric anti-hbv agents | |
| EP3370723A4 (fr) | Traitement d'une infection par le virus de l'hépatite delta | |
| EP3848397A4 (fr) | Protéine de fusion et son application dans la préparation d'un médicament pour le traitement d'une tumeur et/ou d'une infection virale | |
| EP4251615C0 (fr) | Dérivés de spiro[3.3]heptane pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| EP3344640A4 (fr) | Dérivés d'aminoglycoside et leurs utilisations dans le traitement de troubles génétiques | |
| EP3400231A4 (fr) | Dérivés d'aminoglycoside et leurs utilisations dans le traitement d'infections microbiennes | |
| EP3472133A4 (fr) | Inhibiteurs de perk et utilisations associées dans le traitement de maladies associées à des protéines sujettes à l'agrégation |